查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1820308

2025 年至 2033 年帶因者篩檢市場規模、佔有率、趨勢及預測（按類型、醫療狀況、技術、最終用戶和地區）

Carrier Screening Market Size, Share, Trends and Forecast by Type, Medical Condition, Technology, End User, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 141 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球帶因者篩檢市場規模達20億美元。展望未來， IMARC Group預計到2033年，該市場規模將達到45億美元，2025-2033年期間的複合年成長率（CAGR）為9.3%。目前，北美佔據市場主導地位，佔有40%的顯著佔有率。這種主導地位得益於先進的醫療基礎設施、基因檢測技術的廣泛應用以及人們對遺傳性疾病的認知不斷提高。

攜帶者篩檢市場的一個重要促進因素是人們越來越重視遺傳疾病的早期發現和預防。基因組學和分子診斷技術的進步提高了攜帶者篩檢的準確性和可近性，使得人們能夠在懷孕前或懷孕期間識別潛在的遺傳風險。醫療保健專業人員和患者對主動遺傳諮詢重要性的認知不斷提高，進一步刺激了需求。此外，遺傳性疾病盛行率的上升以及政府倡導生殖健康的支持性政策也促進了市場成長。例如，2024年11月，澳洲一項基於夫婦的遺傳攜帶者篩檢計畫在懷孕前或懷孕初期對10,038對夫婦進行了超過1,281個基因的檢測。其中，90.7%完成了篩檢，1.9%被確定為具有較高的遺傳疾病遺傳風險，這些疾病與90個基因相關，主要是體染色體隱性遺傳。在高風險夫婦中，76.6%的人在三個月內尋求或計劃進行生殖干預。這種轉變凸顯了人們越來越重視客製化醫療保健方法並減少遺傳健康問題的潛在影響。

美國憑藉著強大的醫療基礎設施和尖端技術創新，在推動帶因者篩檢市場發展方面發揮關鍵作用。美國領先的生物技術公司和診斷實驗室正引領高精度、高效率基因檢測解決方案的開發。例如，LGC Clinical Diagnostics 於 2024 年推出了 Seraseq 攜帶者篩檢 DNA 混合物，該混合物包含 48 個基因的 54 個關鍵遺傳變異，支持臨床實驗室驗證基於 NGS 的擴展攜帶者篩檢檢測方法，以評估遺傳風險。良好的監管架構加上大量的研發投入，加速了帶因者篩檢在不同醫療環境中的應用。此外，提高公眾遺傳健康意識的舉措以及將先進篩檢技術廣泛融入常規醫療保健，進一步鞏固了美國在攜帶者篩檢市場的全球領先地位。

攜帶者篩檢市場趨勢：

基因技術的不斷進步

基因技術的不斷創新推動著攜帶者篩檢市場的成長。分子診斷檢測技術的進步催生了更新、更優的方法，例如可同時篩檢多種遺傳疾病的新一代定序 (NGS)。這些技術的發展和改進不僅降低了基因檢測的成本，也提高了公眾的可近性。醫療保健提供者因此能夠提供更精準的帶因者篩檢服務。隨著對遺傳疾病認知的不斷加深以及篩檢工具的改進，攜帶者篩檢市場也得到了顯著發展。全基因組定序和 CRISPR-Cas9 等基因技術的進步尤其顯著。在基因組編輯方面，與 ZFN 或 TALEN 等先前技術相比，CRISPR 的準確率可高達 90%。目前，CRISPR 研究的基本試劑盒售價僅 65 至 200 美元，成本大幅下降。

意識和需求不斷提升

由於對早期遺傳疾病檢測的需求不斷成長，攜帶者篩檢市場前景樂觀。隨著越來越多的個人和夫婦希望預防此類遺傳疾病，攜帶者篩檢測試也日益普及。衛生機構不斷增加的教育計畫以及將遺傳諮詢納入標準醫療保健服務，正在推動市場的成長。此外，隨著人們對遺傳疾病認知的不斷提高，以及對疾病早期發現和預防的重視，人們選擇攜帶者篩檢的趨勢也日益增強。預計這一趨勢將在未來持續下去，並保持市場的上升趨勢，因為及時發現可以提高生活品質和生育選擇。一項調查研究調查了患者對基因攜帶者篩檢 (GCS) 的態度和認知，重點關注了他們對這項技術的理解、看法和接受程度，結果顯示，47%（n=245）的患者了解該技術。該研究關注了患者對 GCS 認知度的差距，並強調了改善諮詢和教育的重要性。

政府角色和報銷

政府的政策和行動以及積極的報銷政策趨勢推動了攜帶者篩選產業的發展。衛生和政府政策制定者開始認知到產前篩檢對於預防遺傳疾病傳播至關重要。一項由政府研究人員進行的研究利用新一代定序 (NGS) 評估攜帶者頻率並識別北印度人群中常見遺傳疾病的致病變異，結果顯示，200 名參與者中有 52 名（26%）被確診為至少一種疾病的攜帶者。因此，政府已採取措施將攜帶者篩檢納入國家醫療保健計劃和保險政策框架內的強制性服務清單。由於報銷政策降低了檢測成本，使患者更容易獲得，這些檢測也越來越受歡迎。此外，政府加大了基因篩檢技術研發的資金投入，從而促進了該產業的擴張。這些支持性措施意義重大，因為它們有助於促進攜帶者篩檢的普及，進而增強該產業的發展。

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 二手資料
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

第5章：全球攜帶者篩檢市場

  • 市場概況
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場細分：依類型

  • 擴大攜帶者篩檢
    • 關鍵部分
      • 客製化面板測試
      • 預先設計的面板測試
  • 針對性疾病帶因者篩檢

第7章：市場區隔：依醫療狀況

  • 肺部疾病
  • 血液疾病
  • 神經系統疾病
  • 其他

第8章：市場區隔：依技術

  • DNA定序
  • 聚合酶鍊式反應
  • 微陣列
  • 其他

第9章：市場區隔：依最終用戶

  • 醫院和診所
  • 參考實驗室
  • 其他

第10章：市場細分：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第 11 章：SWOT 分析

第 12 章：價值鏈分析

第 13 章：波特五力分析

第 14 章：價格分析

第 15 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Fulgent Genetics
    • Gene：By Gene Ltd. (MyDNA)
    • Illumina Inc.
    • Invitae Corporation
    • MedGenome Labs Ltd.
    • Myriad Genetics Inc.
    • Natera Inc.
    • OPKO Health Inc.
    • Quest Diagnostics
    • Sema4
    • Thermo Fisher Scientific Inc.
Product Code: SR112025A4417

The global carrier screening market size reached USD 2.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.5 Billion by 2033, exhibiting a growth rate (CAGR) of 9.3% during 2025-2033. North America currently dominates the market, holding a significant share of 40%. This dominance can be attributed to advanced healthcare infrastructure, widespread adoption of genetic testing technologies, and increasing awareness of inherited genetic conditions.

A significant driver of the carrier screening market is the growing emphasis on early detection and prevention of genetic disorders. Advances in genomics and molecular diagnostics have enhanced the accuracy and accessibility of carrier screening, enabling the identification of potential genetic risks before or during pregnancy. Increasing awareness among healthcare professionals and patients about the importance of proactive genetic counseling has further fueled demand. Additionally, the rising prevalence of inherited disorders and supportive governmental policies advocating for reproductive health have bolstered market growth. For instance, in November 2024, a couple-based genetic carrier screening program in Australia tested 10,038 couples for over 1,281 genes before or early in pregnancy. Of these, 90.7% completed screening, with 1.9% identified as having a higher risk of passing on genetic conditions tied to 90 genes, mainly autosomal recessive. Among high-risk couples, 76.6% pursued or planned reproductive interventions within three months. This shift highlights a growing dedication to tailored healthcare approaches and reducing the potential impact of genetic health concerns.

The United States plays a pivotal role in advancing the carrier screening market through robust healthcare infrastructure and cutting-edge technological innovation. Leading biotechnology firms and diagnostic laboratories in the US are spearheading the development of highly accurate and efficient genetic testing solutions. For instance, in 2024, LGC Clinical Diagnostics introduced the Seraseq Carrier Screening DNA Mix, featuring 54 key genetic variants across 48 genes, supporting clinical labs in validating NGS-based expanded carrier screening assays for genetic risk assessment. Favorable regulatory frameworks, combined with substantial investments in research and development, have accelerated the adoption of carrier screening across diverse healthcare settings. Additionally, initiatives to increase public awareness about genetic health and widespread integration of advanced screening technologies into routine healthcare have further strengthened the US's position as a global leader in the carrier screening market.

Carrier Screening Market Trends:

Continual Advancements in Genetic Technology

Emerging innovations in genetic technology are supporting the carrier screening market growth. Advancements in molecular diagnostic testing have led to the development of newer and better methods, such as the next-generation sequencing (NGS) for screening several genetic disorders at once. These technological developments and improvements have not only contributed to the lowering of the cost of genetic testing, but also to its accessibility to the public. Healthcare providers are thus able to provide improved and accurate carrier screening, with numerous developments in the knowledge of genetic disorders to grow along with the enhancements in screening instruments contributing to the progress of the market for carrier screening. Among the advances in genetic technology are Whole Genome Sequencing and CRISPR-Cas9. When it comes to genome editing, CRISPR can reach up to 90% accuracy when compared to previous technologies like ZFNs or TALENs. Basic kits for CRISPR-based studies can now be purchased for as little as USD65 to USD200, marking a considerable decrease in cost.

Rising Awareness and Demand

The carrier screening market outlook is positive due to the rising demand for early genetic disorders detection. Carrier screening tests are also on the rise as more individuals and couples want to be protected from such inherited conditions. Increased education programs by health bodies and incorporating genetic counseling into standard healthcare services are supporting the growth of the market. Furthermore, as there is increasing awareness of genetic diseases, coupled with the shift for early detection of diseases and prevention, individuals are opting for carrier screening. This trend is expected to continue in the future, and maintain the market's upward trend, as timely detection enhances the quality of life and reproductive choices. Forty-seven percent (n=245) of patients were aware of genetic carrier screening (GCS), according to a survey study that examines patients' attitudes and awareness of the technique, concentrating on their comprehension, opinions, and acceptance of it. It draws attention to a patient awareness gap regarding GCS and stresses the significance of improved counselling and education.

Government Roles and Reimbursements

The carrier screening industry is propelled by governmental policies and actions, as well as a positive trend in reimbursement policies. Health and government policy makers are beginning to understand that pre-natal screenings are essential in preventing the spread of genetic disorders. In a study conducted by government researchers utilizing next-generation sequencing (NGS) to assess carrier frequency and identify pathogenic variants of prevalent genetic disorders within the North Indian population, 52 out of 200 participants (26%) were identified as carriers of at least one disorder. Consequently, there are measures to introduce carrier screening into the list of mandatory services provided within the framework of state health care programs and insurance policies. These tests are growing popular as reimbursement policies have made them cheaper and thus more accessible to clients. Also, there is an increase in government funding that supports research and development in genetic screening technologies and therefore the expansion occurring in the industry. Such supportive measures are valuable as they help to facilitate the increased use of carrier screening, which in turn strengthens the industry.

Carrier Screening Industry Segmentation:

Analysis by Type:

  • Expanded Carrier Screening
    • Customized Panel Testing
    • Predesigned Panel Testing
  • Targeted Disease Carrier Screening

Expanded carrier screening leads the market in 2024. Expanded carrier screening provides added information as to various conditions including rare ones, due to which it is a preferred option both by healthcare providers as well as the patients. Its ability to offer comprehensive results of an individual's carrier status for multiple disorders in a single test has propelled its popularity. It also helps to provide better diagnostic accuracy and assists in making better decisions as to family planning and management. The increasing focus on the genetic health of both parents-to-be and the accessibility of new and more sophisticated carrier detection methods add to the continued popularity of more extensive carrier screening, which cements the leading position of the market.

Analysis by Medical Condition:

  • Pulmonary Conditions
  • Hematological Conditions
  • Neurological Conditions
  • Others

Pulmonary conditions leads the market in 2024. Pulmonary conditions represents the largest market segment in the market. Diseases, including cystic fibrosis are more prevalent with serious effects on health, therefore, screening should be done early and correctly to contain the consequences. Current opinions regarding the importance of carrier screening for pulmonary conditions are also worth considering, as the timely identification of the potential carriers and the development of an effective treatment plan can ultimately save the patient's life and improve their quality of living. Reliable screening tests and focus on the research aspect in the carrier field also play a key role in significant market share being dominated by the pulmonary conditions screening. The focus on disease prevention and genetic testing also bolster the centrality of pulmonary disorders in the sector more widely.

Analysis by Technology:

  • DNA Sequencing
  • Polymerase Chain Reaction
  • Microarrays
  • Others

DNA sequencing lead the market with around 40.1% of market share in 2024. Carrier testing by DNA sequencing has been identified to be the most dominant segment within the market by technology. This enhanced science helps in the characterization of DNA materials by finding possible mutations that may determine the carrier status of such inherited ailments. Advancements in DNA sequencing such as high precision, efficiency in generating sequence data and the reduced cost compared to other methods have made DNA sequencing the carrier screening technique of choice. The need to make early provisions in cases of genetic disorders and diseases makes it instrumental in offering adequate and accurate genetic information. With the advancement in sequencing technology, carrier screening has been through more depth and spectrum in genetic analysis.

Analysis by End User:

  • Hospitals and Clinics
  • Reference Laboratories
  • Others

Hospitals and clinics leads the market with around 47% of market share in 2024. These are the typical medical facilities where clients can get access to genetic diagnostics. Carrier testing involves the performance of exhaustive screening tests and subsequent counseling- an aspect that hospitals and clinics are well equipped to handle through their necessary infrastructure, personnel, and equipment. These services are translated to make access to carrier screening widespread since the facilities offering prenatal and preconception care incorporate this service. Also, the trust and credibility that are attributed to hospitals and clinics push more individuals into selecting carrier screening. With the existing expansion of genetic testing across these healthcare institutions, the market fundamentals are strengthened behind the key players, which positively contributes to the promotion of carrier screening services.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2024, North America accounted for the largest market share of over 40%. According to the report, North America represents the largest regional market for carrier screening. North America is the largest market share due to better healthcare facilities, increased awareness levels, and supportive government laws to carry out such genetic tests. The availability of all major genetic testing companies and the on-going research regarding genetics also play a role in placing the area at the top. In North America, there is a relatively greater focus on the prevention of diseases, and usage of carrier screenings is also relatively high. Moreover, the access to desirable insurance coverage for genetic tests creates additional demand for the market. The increased consumer interest in carrier screenings, especially in personalized medication and early disease diagnosis, and North America's advanced healthcare industry as well as its active approach to genetic screening will continue to foster its growth in the global market.

Key Regional Takeaways:

United States Carrier screening Market Analysis

US accounts for 90% share of the market in North America. Rising cases of genetic

disorders and an increased awareness toward early diagnosis drive the United States carrier screening industry. It has been estimated by the Office of Disease Prevention and Health Promotion that nearly 3% of 4 million babies born each year in the United States have birth defects or genetic disorders, making this an area worth carrying out screening on. Key growth drivers in this industry are the expanded carrier screening that tests for more than 400 genetic disorders, as the data of Repromed Fertility Specialists would show, and technological developments within next-generation sequencing (NGS). The country has more than 7,000 genetic counsellors, as per the data from National Institute of Health, ensuring a sound health system for guidance to the expecting parents. The market is also driven by government support for newborn screening programs and mandates for coverage under health insurance policies.

High participation rates in reproductive treatments, such as IVF, accounting for 2.5% of all births in 2022, based on the SART Clinic-specific ART data published by the Society for Assisted Reproductive Technology, further increase the urgency for carrier screening as part of pre-implantation genetic testing. Additionally, screening is becoming more widely available and reasonably priced because to the growing awareness of personalised medicine and the growth of direct-to-consumer genetic testing companies like 23andMe and Invitae.

Europe Carrier screening Market Analysis

Growing awareness of genetic disorders and government-supported healthcare programs are driving the carrier screening industry in Europe. According to an industrial report, with nearly 3.5 million births per year in the region, the demand for genetic testing, including carrier screening, is growing rapidly to prevent inherited diseases such as cystic fibrosis, which is reported to affect about 1 in 2,500 babies. Due to their comprehensive insurance coverage and strong healthcare systems, countries like the UK, Germany, and France are leading the way in the adoption of modern genetic testing. To encourage early detection and informed reproductive decisions, the European Society of Human Genetics has also emphasized the importance of population-based carrier screening. The presence of reliable biotechnology companies and research centers enhances the availability of state-of-the-art carrier screening technologies. The industry is also being driven by improvements in the accessibility and accuracy of screening tests brought about by increased funding for genetic research and partnerships between academic institutions and healthcare providers.

Asia Pacific Carrier Screening Market Analysis

The market for carrier screening is expanding significantly in the Asia-Pacific area due to growing healthcare awareness and a greater emphasis on mother and child health. Having nearly 9 million (in 2023) and 25 million births a year (UNICEF stats), respectively, China and India are a hub of massive scope for carrier screening programs. Increased prevalence of congenital disorders such as thalassemia, sometimes affecting considerable sections of the populations in certain geographical regions, provides a rationale to conduct testing for these conditions. Vietnam accounted for the greatest percentage, having 51.5% with thalassemia while Cambodia 39.5%, Laos 26.8%, Thailand 20.1%, and Malaysia 17.3%, as per reports. Another stimulus for the sector is governmental measures: thus, thalassaemia-screening programs that are compulsory throughout India have fostered growth for the sector. Advances in genetics testing technology boost usage. Emergence of more regional screening operations offering competitive rates also adds fuel to this engine. Another factor for the region includes the increasing requirement for medical tourism in countries like Malaysia and Thailand, which have been known for their low cost genetic testing provision.

Latin America Carrier Screening Market Analysis

Improving maternal health and reducing incidence of inherited disorders are the increasing concerns that lead to the increasing market for carrier screening in Latin America. The two countries that use genetic screening the most in the region is Brazil with 2.5 million births annually, according to an industrial report. Programs targeting illnesses that are more prevalent in particular areas increase the need for carrier screening, such as sickle cell anaemia and cystic fibrosis. Public health initiatives such as newborn screening programs in Brazil support early diagnosis of genetic disorders. Other factors, which are responsible for market expansion, include middle-class people who have better awareness of genetic issues and growing demand for private medical services. There is also co-operation between regional health facilities and foreign genetic testing companies that improve accessability.

Middle East and Africa Carrier Screening Market Analysis

Due to the high rate of consanguineous marriages, which raise the risk of genetic illnesses, the Middle East and Africa region is seeing a surge in demand for carrier screening. Consanguineous marriages make up more than half of all unions in several Middle Eastern nations, which increases the prevalence of hereditary diseases including thalassaemia and sickle cell anaemia. To avoid genetic disorders, national programs such as the premarital screening program of Saudi Arabia are carrier screening dependent, which in turn drives market growth significantly. Carrier screening is in greater demand in Africa because of increased efforts in treating sickle cell disease, which affects up to 3% of births, as per reports. The availability of advanced genetic testing options in the region is also enhanced by increased investments in health infrastructure and collaboration with foreign bodies.

Competitive Landscape:

Career screening companies are rapidly increasing their technological advancement and market coverage. Various other genetic testing companies are also committing resources to the improvement of sensitivity and expanding the list of diseases amenable to detection through genetic testing. They are also entering into various affiliations and service agreements with healthcare service providers and facilities to diversify their service delivery portfolios. For instance, in 2024, Invitae sold reproductive health assets, including carrier and non-invasive prenatal screening, to Natera for $52.5 million, transferring customers and sales representatives to Natera for seamless service continuity. These players are looking to adopt revolutionary technologies such as NGS that will enable them to make their carrier screening more accurate and inclusive. Also, they are to increase awareness efforts in promoting the use of carrier screening among the populace. Key strategies of the market identified as the improvement of accessibility by making prices more competitive, as well as the expansion of the territory, make certain critical players strengthen their positions and promote the development of the market.

The report provides a comprehensive analysis of the competitive landscape in the carrier screening market with detailed profiles of all major companies, including:

  • Fulgent Genetics
  • Gene By Gene Ltd. (MyDNA)
  • Illumina Inc.
  • Invitae Corporation
  • MedGenome Labs Ltd.
  • Myriad Genetics Inc.
  • Natera Inc.
  • OPKO Health Inc.
  • Quest Diagnostics
  • Sema4
  • Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

  • 1.How big is the carrier screening market?
  • 2.What is the future outlook of the carrier screening market?
  • 3.What are the key factors driving the carrier screening market?
  • 4.Which region accounts for the largest carrier screening market share?
  • 5.Which are the leading companies in the global carrier screening market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Carrier Screening Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Expanded Carrier Screening
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Customized Panel Testing
      • 6.1.2.2 Predesigned Panel Testing
    • 6.1.3 Market Forecast
  • 6.2 Targeted Disease Carrier Screening
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Medical Condition

  • 7.1 Pulmonary Conditions
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Hematological Conditions
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Neurological Conditions
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Technology

  • 8.1 DNA Sequencing
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Polymerase Chain Reaction
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Microarrays
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Reference Laboratories
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Fulgent Genetics
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
    • 15.3.2 Gene By Gene Ltd. (MyDNA)
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Illumina Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Invitae Corporation
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
    • 15.3.5 MedGenome Labs Ltd.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 Myriad Genetics Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Natera Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
    • 15.3.8 OPKO Health Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Quest Diagnostics
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Sema4
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
    • 15.3.11 Thermo Fisher Scientific Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Carrier Screening Market: Major Drivers and Challenges
  • Figure 2: Global: Carrier Screening Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Carrier Screening Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Carrier Screening Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Carrier Screening Market: Breakup by Medical Condition (in %), 2024
  • Figure 6: Global: Carrier Screening Market: Breakup by Technology (in %), 2024
  • Figure 7: Global: Carrier Screening Market: Breakup by End User (in %), 2024
  • Figure 8: Global: Carrier Screening Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Carrier Screening (Expanded Carrier Screening) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Carrier Screening (Expanded Carrier Screening) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Carrier Screening (Targeted Disease Carrier Screening) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Carrier Screening (Targeted Disease Carrier Screening) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Carrier Screening (Pulmonary Conditions) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Carrier Screening (Pulmonary Conditions) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Carrier Screening (Hematological Conditions) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Carrier Screening (Hematological Conditions) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Carrier Screening (Neurological Conditions) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Carrier Screening (Neurological Conditions) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Carrier Screening (Other Medical Conditions) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Carrier Screening (Other Medical Conditions) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Carrier Screening (DNA Sequencing) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Carrier Screening (DNA Sequencing) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Carrier Screening (Polymerase Chain Reaction) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Carrier Screening (Polymerase Chain Reaction) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Carrier Screening (Microarrays) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Carrier Screening (Microarrays) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Carrier Screening (Other Technologies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Carrier Screening (Other Technologies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Carrier Screening (Hospitals and Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Carrier Screening (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Carrier Screening (Reference Laboratories) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Carrier Screening (Reference Laboratories) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Carrier Screening (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Carrier Screening (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: North America: Carrier Screening Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: North America: Carrier Screening Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: United States: Carrier Screening Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: United States: Carrier Screening Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Canada: Carrier Screening Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Canada: Carrier Screening Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Asia-Pacific: Carrier Screening Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Asia-Pacific: Carrier Screening Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: China: Carrier Screening Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: China: Carrier Screening Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Japan: Carrier Screening Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Japan: Carrier Screening Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: India: Carrier Screening Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: India: Carrier Screening Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: South Korea: Carrier Screening Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: South Korea: Carrier Screening Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Australia: Carrier Screening Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Australia: Carrier Screening Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Indonesia: Carrier Screening Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Indonesia: Carrier Screening Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Others: Carrier Screening Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Others: Carrier Screening Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Europe: Carrier Screening Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Europe: Carrier Screening Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Germany: Carrier Screening Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Germany: Carrier Screening Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: France: Carrier Screening Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: France: Carrier Screening Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: United Kingdom: Carrier Screening Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: United Kingdom: Carrier Screening Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Italy: Carrier Screening Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Italy: Carrier Screening Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Spain: Carrier Screening Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Spain: Carrier Screening Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Russia: Carrier Screening Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Russia: Carrier Screening Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Others: Carrier Screening Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Others: Carrier Screening Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Latin America: Carrier Screening Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Latin America: Carrier Screening Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Brazil: Carrier Screening Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Brazil: Carrier Screening Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Mexico: Carrier Screening Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Mexico: Carrier Screening Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Others: Carrier Screening Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Others: Carrier Screening Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Middle East and Africa: Carrier Screening Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Middle East and Africa: Carrier Screening Market: Breakup by Country (in %), 2024
  • Figure 83: Middle East and Africa: Carrier Screening Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Global: Carrier Screening Industry: SWOT Analysis
  • Figure 85: Global: Carrier Screening Industry: Value Chain Analysis
  • Figure 86: Global: Carrier Screening Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Carrier Screening Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Carrier Screening Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Carrier Screening Market Forecast: Breakup by Medical Condition (in Million USD), 2025-2033
  • Table 4: Global: Carrier Screening Market Forecast: Breakup by Technology (in Million USD), 2025-2033
  • Table 5: Global: Carrier Screening Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 6: Global: Carrier Screening Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Carrier Screening Market: Competitive Structure
  • Table 8: Global: Carrier Screening Market: Key Players